OBJECTIVE: This study aimed to determine whether the plasma levels of matrix metalloproteinase-9 (MMP-9) or tissue inhibitor of metalloproteinases-1 (TIMP-1) were altered in patients with a history of symptomatic in-stent restenosis (ISR). METHODS AND RESULTS: A group of 158 patients with a history of ISR were compared with 128 symptom-free patients. Plasma samples and a detailed risk factor history were collected. Plasma samples were analyzed for pro-MMP-9 and latent MMP-9 and active MMP-9, latent MMP-3, and TIMP-1. Several variables were associated with ISR, including index coronary disease extent and severity (number of diseased vessels and American College of Cardiology/American Heart Association lesion classification), number, diameter, and total length of stent(s) inserted, and plasma high-density lipoprotein cholesterol. Plasma active MMP-9 (odds ratio, 1.96; 95% CI, 1.43 to 2.69) showed independent risk association with ISR. Patients with multiple sites of ISR had significantly higher levels of active MMP-9 compared with patients with only a single ISR lesion or no ISR. CONCLUSIONS: Plasma active MMP-9 levels may be a useful independent predictor of bare metal stent ISR.
OBJECTIVE: This study aimed to determine whether the plasma levels of matrix metalloproteinase-9 (MMP-9) or tissue inhibitor of metalloproteinases-1 (TIMP-1) were altered in patients with a history of symptomatic in-stent restenosis (ISR). METHODS AND RESULTS: A group of 158 patients with a history of ISR were compared with 128 symptom-free patients. Plasma samples and a detailed risk factor history were collected. Plasma samples were analyzed for pro-MMP-9 and latent MMP-9 and active MMP-9, latent MMP-3, and TIMP-1. Several variables were associated with ISR, including index coronary disease extent and severity (number of diseased vessels and American College of Cardiology/American Heart Association lesion classification), number, diameter, and total length of stent(s) inserted, and plasma high-density lipoprotein cholesterol. Plasma active MMP-9 (odds ratio, 1.96; 95% CI, 1.43 to 2.69) showed independent risk association with ISR. Patients with multiple sites of ISR had significantly higher levels of active MMP-9 compared with patients with only a single ISR lesion or no ISR. CONCLUSIONS: Plasma active MMP-9 levels may be a useful independent predictor of bare metal stent ISR.
Authors: Dammanahalli K Jagadeesha; Maysam Takapoo; Botond Banfi; Ramesh C Bhalla; Francis J Miller Journal: Cardiovasc Res Date: 2011-11-18 Impact factor: 10.787
Authors: Luis Rodriguez-Menocal; Yuntao Wei; Si M Pham; Melissa St-Pierre; Sen Li; Keith Webster; Pascal Goldschmidt-Clermont; Roberto I Vazquez-Padron Journal: Atherosclerosis Date: 2009-10-06 Impact factor: 5.162
Authors: Simon Jönsson; Anna Lundberg; Hanna Kälvegren; Ida Bergström; Aleksander Szymanowski; Lena Jonasson Journal: PLoS One Date: 2011-04-29 Impact factor: 3.240
Authors: Svitlana Demyanets; Ioannis Tentzeris; Rudolf Jarai; Katharina M Katsaros; Serdar Farhan; Anna Wonnerth; Thomas W Weiss; Johann Wojta; Walter S Speidl; Kurt Huber Journal: Cytokine Date: 2014-03-27 Impact factor: 3.861